vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and JFB Construction Holdings (JFB). Click either name above to swap in a different company.
JFB Construction Holdings is the larger business by last-quarter revenue ($16.0M vs $15.0M, roughly 1.1× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -11.7%, a 13.5% gap on every dollar of revenue. CHAMPIONS ONCOLOGY, INC. produced more free cash flow last quarter ($-2.0M vs $-9.1M).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
CSBR vs JFB — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $16.0M |
| Net Profit | $268.0K | $-1.9M |
| Gross Margin | 51.7% | 4.3% |
| Operating Margin | 1.2% | -12.7% |
| Net Margin | 1.8% | -11.7% |
| Revenue YoY | 11.5% | — |
| Net Profit YoY | -63.2% | — |
| EPS (diluted) | $0.02 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $16.0M | ||
| Q3 25 | $14.0M | $5.0M | ||
| Q2 25 | $12.4M | $3.7M | ||
| Q1 25 | $17.0M | $5.9M | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $14.1M | — | ||
| Q2 24 | $14.0M | — | ||
| Q1 24 | $12.0M | — |
| Q4 25 | $268.0K | $-1.9M | ||
| Q3 25 | $-436.0K | $-1.1M | ||
| Q2 25 | $-1.8M | $-2.4M | ||
| Q1 25 | $4.5M | $30.3K | ||
| Q4 24 | $728.0K | — | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $-109.0K | — | ||
| Q1 24 | $-2.5M | — |
| Q4 25 | 51.7% | 4.3% | ||
| Q3 25 | 42.9% | 14.9% | ||
| Q2 25 | 41.1% | 7.0% | ||
| Q1 25 | 61.2% | 24.8% | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | -12.7% | ||
| Q3 25 | -3.8% | -22.6% | ||
| Q2 25 | -16.2% | -67.2% | ||
| Q1 25 | 26.4% | -0.5% | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | -1.9% | — | ||
| Q1 24 | -21.4% | — |
| Q4 25 | 1.8% | -11.7% | ||
| Q3 25 | -3.1% | -21.3% | ||
| Q2 25 | -14.9% | -64.3% | ||
| Q1 25 | 26.4% | 0.5% | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 9.3% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | -21.1% | — |
| Q4 25 | $0.02 | $0.06 | ||
| Q3 25 | $-0.03 | $-0.11 | ||
| Q2 25 | $-0.12 | $-0.26 | ||
| Q1 25 | $0.31 | $0.00 | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $-0.01 | — | ||
| Q1 24 | $-0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $37.8M |
| Total Assets | $30.2M | $40.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | — | ||
| Q3 25 | $10.3M | — | ||
| Q2 25 | $9.8M | — | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $2.6M | — | ||
| Q1 24 | $4.5M | — |
| Q4 25 | $4.2M | $37.8M | ||
| Q3 25 | $3.5M | $11.6M | ||
| Q2 25 | $3.8M | $10.1M | ||
| Q1 25 | $5.5M | $11.0M | ||
| Q4 24 | $681.0K | — | ||
| Q3 24 | $-332.0K | — | ||
| Q2 24 | $-1.9M | — | ||
| Q1 24 | $-2.1M | — |
| Q4 25 | $30.2M | $40.0M | ||
| Q3 25 | $30.5M | $14.0M | ||
| Q2 25 | $32.3M | $12.0M | ||
| Q1 25 | $30.6M | $13.3M | ||
| Q4 24 | $25.2M | — | ||
| Q3 24 | $24.9M | — | ||
| Q2 24 | $26.1M | — | ||
| Q1 24 | $26.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-9.0M |
| Free Cash FlowOCF − Capex | $-2.0M | $-9.1M |
| FCF MarginFCF / Revenue | -13.1% | -57.2% |
| Capex IntensityCapex / Revenue | 1.6% | 1.1% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-12.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-9.0M | ||
| Q3 25 | $600.0K | $-719.0K | ||
| Q2 25 | $6.9M | $-2.5M | ||
| Q1 25 | $490.0K | $392.8K | ||
| Q4 24 | $-283.0K | — | ||
| Q3 24 | $311.0K | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-919.0K | — |
| Q4 25 | $-2.0M | $-9.1M | ||
| Q3 25 | $554.0K | $-730.9K | ||
| Q2 25 | $6.6M | $-2.5M | ||
| Q1 25 | $448.0K | $347.0K | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -13.1% | -57.2% | ||
| Q3 25 | 4.0% | -14.7% | ||
| Q2 25 | 53.5% | -68.0% | ||
| Q1 25 | 2.6% | 5.9% | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | 1.1% | ||
| Q3 25 | 0.3% | 0.2% | ||
| Q2 25 | 2.0% | 0.0% | ||
| Q1 25 | 0.2% | 0.8% | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | 12.96× | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
JFB
| Nonrelated Party | $12.5M | 78% |
| Other | $3.5M | 22% |
